137196-67-9

Usage

Uses

Used in Pharmaceutical Industry:
SDZ-205 557 HCL is used as a selective antagonist for the SR-3 and SR-4 receptors, which are involved in various physiological processes. By blocking these receptors, it can potentially be used to modulate the effects of certain drugs or to study the functions of these receptors in the body.
Used in Research and Development:
In the field of research and development, SDZ-205 557 HCL can be employed as a research tool to investigate the roles of SR-3 and SR-4 receptors in various biological processes. This can lead to a better understanding of their functions and the development of new therapeutic strategies targeting these receptors.
Used in Drug Discovery:
SDZ-205 557 HCL can be utilized in drug discovery efforts to identify potential therapeutic agents that can modulate the activity of SR-3 and SR-4 receptors. This may lead to the development of new drugs for the treatment of various diseases and conditions related to the dysfunction of these receptors.
Used in Drug Delivery Systems:
Similar to gallotannin, SDZ-205 557 HCL can also be incorporated into novel drug delivery systems to enhance its applications and efficacy. By using carriers such as organic and metallic nanoparticles, the delivery, bioavailability, and therapeutic outcomes of SDZ-205 557 HCL can be improved, potentially leading to more effective treatments for various conditions.

Biological Activity

5-HT 3 /5-HT 4 receptor antagonist.

InChI:InChI=1/C14H21ClN2O3.ClH/c1-4-17(5-2)6-7-20-14(18)10-8-11(15)12(16)9-13(10)19-3;/h8-9H,4-7,16H2,1-3H3;1H

Upstream product

• 7206-70-4 4-amino-5-chloro-2-methoxybenzoic acid 
• 100-37-8 2-(Diethylamino)ethanol 

Relevant academic research and scientific papers

Drug evolution concept in drug design: 1. Hybridization method

A novel concept, "drug evolution", is proposed to develop chemical libraries that have a high probability of finding drugs or drug candidates. It converts biological evolution into chemical evolution. In this paper, we present "hybridization" drug evolution, which is the equivalent of sexual recombination of parental genomes in biological evolution. The hybridization essentially shuffles the building blocks of the parent drugs and ought to drug(s); no drug evolution can otherwise occur. We hybridized two drugs, benzocaine and metoclopramide and generated 16 molecules that include the parent drugs, four known drugs, and two molecules whose therapeutic activities are reported. The unusually high number of drugs and drug candidates in the library encourages high expectations of finding new drug(s) or drug candidate(s) within the remaining eight compounds. Interestingly, the therapeutic applications of the eight drugs or drug candidates in the library are fairly diverse as 38 therapeutic applications and 25 molecular targets are counted. Therefore, the library fits as a general chemical library for unspecified therapeutic activities. The hybridization of other two drugs, aspirin and cresotamide, is also described to demonstrate the generality of the method.

Synthesis and biological activity of a series of aryl tropanyl esters and amides chemically related to 1H-indole-3-carboxylic acid endo 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester. Development of a 5-HT4 agonist endowed with potent antinocicepti

A series of aryl tropanyl esters and amides related to 1H-indole-3-carboxylic acid endo 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (ICS 205930, CAS 89565-68-4) were synthesized and evaluated for antinociceptive activity using the hot-plate test. Of these,